Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 3
2020 12
2021 9
2022 18
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide.
Ravindra N, Dillon LW, Gui G, Smith M, Gondek LP, Jones RJ, Corner A, Hourigan CS, Ambinder AJ. Ravindra N, et al. Bone Marrow Transplant. 2024 Mar;59(3):428-430. doi: 10.1038/s41409-023-02189-9. Epub 2024 Jan 5. Bone Marrow Transplant. 2024. PMID: 38182672 No abstract available.
Persistent IDH mutations are not associated with increased relapse or death in patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamide.
Ravindra N, Dillon LW, Gui G, Smith M, Gondek LP, Jones RJ, Corner A, Hourigan CS, Ambinder AJ. Ravindra N, et al. medRxiv [Preprint]. 2023 Aug 21:2023.08.14.23294087. doi: 10.1101/2023.08.14.23294087. medRxiv. 2023. PMID: 37662423 Free PMC article. Updated. Preprint.
Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration.
Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall SA, Gondek LP, Bashey A, Keyzner A, Tamari R, Grunwald MR, Abedin S, Nadiminti KV, Iqbal M, Gerds AT, Viswabandya A, McCurdy SR, Al Malki MM, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S. Jain T, et al. Haematologica. 2023 Dec 1;108(12):3321-3332. doi: 10.3324/haematol.2023.283426. Haematologica. 2023. PMID: 37408464 Free PMC article.
Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration.
Jain T, Tsai HL, Elmariah H, Vachhani P, Karantanos T, Wall S, Gondek L, Bashey A, Keyzner A, Tamari R, Grunwald M, Abedin S, Nadiminti K, Iqbal M, Gerds A, Viswabandya A, McCurdy S, Malki MA, Varadhan R, Ali H, Gupta V, Jones RJ, Otoukesh S. Jain T, et al. Res Sq [Preprint]. 2023 Mar 21:rs.3.rs-2691216. doi: 10.21203/rs.3.rs-2691216/v1. Res Sq. 2023. PMID: 36993719 Free PMC article. Updated. Preprint.
Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.
Webster JA, Reed M, Tsai HL, Ambinder A, Jain T, Dezern AE, Levis MJ, Showel MM, Prince GT, Hourigan CS, Gladstone DE, Bolanos-Meade J, Gondek LP, Ghiaur G, Dalton WB, Paul S, Fuchs EJ, Gocke CB, Ali SA, Huff CA, Borrello IM, Swinnen L, Wagner-Johnston N, Ambinder RF, Luznik L, Gojo I, Smith BD, Varadhan R, Jones RJ, Imus PH. Webster JA, et al. Transplant Cell Ther. 2023 Mar;29(3):182.e1-182.e8. doi: 10.1016/j.jtct.2022.12.018. Epub 2022 Dec 29. Transplant Cell Ther. 2023. PMID: 36587740 Free PMC article.
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source.
Sterling CH, Hughes MS, Tsai HL, Yarkony K, Fuchs EJ, Swinnen LJ, Paul S, Bolaños-Meade J, Luznik L, Imus PH, Ali SA, Jain T, Ambinder A, DeZern A, Huff CA, Gocke CB, Varadhan R, Wagner-Johnston N, Jones RJ, Ambinder RF. Sterling CH, et al. Transplant Cell Ther. 2023 Apr;29(4):267.e1-267.e5. doi: 10.1016/j.jtct.2022.12.009. Epub 2022 Dec 19. Transplant Cell Ther. 2023. PMID: 36549386 Free PMC article. Review.
CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.
Karantanos T, Teodorescu P, Arvanitis M, Perkins B, Jain T, DeZern AE, Dalton WB, Christodoulou I, Paun BC, Varadhan R, Esteb C, Rajkhowa T, Bonifant C, Gondek LP, Levis MJ, Yegnasubramanian S, Ghiaur G, Jones RJ. Karantanos T, et al. Haematologica. 2023 Jul 1;108(7):1886-1899. doi: 10.3324/haematol.2022.281444. Haematologica. 2023. PMID: 36519323 Free PMC article.
46 results